Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

ArriVent BioPharma (AVBP) Assets Average (2024 - 2026)

ArriVent BioPharma has reported Assets Average over the past 3 years, most recently at $341.2 million for Q1 2026.

  • Quarterly results put Assets Average at $341.2 million for Q1 2026, up 39.15% from a year ago — trailing twelve months through Mar 2026 was $341.2 million (up 39.15% YoY), and the annual figure for FY2025 was $304.1 million, up 38.83%.
  • Assets Average reached $341.2 million in Q1 2026 per AVBP's latest filing, up from $329.9 million in the prior quarter.
  • Across five years, Assets Average topped out at $341.2 million in Q1 2026 and bottomed at $242.5 million in Q2 2025.
  • Median Assets Average over the past 3 years was $298.0 million (2025), compared with a mean of $289.5 million.
  • The largest annual shift saw Assets Average decreased 23.82% in 2025 before it surged 39.15% in 2026.
  • Over 3 years, Assets Average stood at $283.8 million in 2024, then grew by 16.22% to $329.9 million in 2025, then increased by 3.45% to $341.2 million in 2026.
  • Business Quant data shows Assets Average for AVBP at $341.2 million in Q1 2026, $329.9 million in Q4 2025, and $298.0 million in Q3 2025.